Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 February 2021 Photo UFS photo archive
The National Control Laboratory for Biological Products (NCL) Building.

There can be no compromise when it comes to the quality of medicines made available to the public.

The UFS-based National Control Laboratory for Biological Products (NCL) is a full member of the international WHO-National Control Laboratory Network for Biologicals and one of 12 laboratories worldwide contracted to perform vaccine testing for the World Health Organisation (WHO). The NCL is also the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of the South African Health Products Regulatory Authority (SAHPRA).

In its role as a vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 

International testing standards

The laboratory received the status of a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) endorsed its quality-management systems as of a high standard according to the International Standards Organisation’s requirements.

With its international testing standards, the NCL must ensure that all its operations – from the way documents are compiled and stored, to the maintenance of equipment and infrastructure, as well as staff competency – are performed according to international guidelines.

The laboratory has all the quality systems in place to ensure high-quality test results. The certificate of Good Manufacturing Compliance received in 2019 indicates that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. This certification is very strict and means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world. The certification offers the South African Health Products Regulatory Authority, the WHO, and other national control laboratories around the world the confidence that the test results from the NCL can be trusted.

Licensed as pharmaceutical manufacturer

The laboratory is also licensed as a pharmaceutical manufacturer. Although the lab does not manufacture, it needs to comply with manufacturing standards. It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications.

News Archive

Death may come in adorable little packages
2015-03-23

The main host of the Lassa virus is the Natal Mulimammate mouse.

Photo: Supplied

Postdoctoral researcher, Abdon Atangana, of the Institute for Groundwater Studies at the university recently published an article online about the Lassa Haemorrhagic fever in the Natural Computing Applications Forum. In addition to the terminal transmissible sickness recognised as Ebola haemorrhagic fever, there is another strain called Lassa haemorrhagic fever.

The disease is classified under the arenaviridae virus family. The first outbreaks of the disease were observed in Nigeria, Liberia, Sierra Leone, and the Central African Republic. However, it was first described in 1969 in the town of Lassa, in Borno State, Nigeria.

The main host of the Lassa virus is the Natal Mulimammate mouse, an animal indigenous to most of Sub-Saharan Africa. The contamination in humans characteristically takes place through exposure to animal excrement through the respiratory or gastrointestinal tracts.

Mouthfuls of air containing tiny particle of infective material are understood to be the most noteworthy way of exposure. It is also possible to acquire the infection through broken skin or mucous membranes that are directly exposed to the infective material.

“The aim of my research was to propose a novel mathematical equation used to describe the spread of the illness amongst pregnant women in West Africa. To achieve this, I used my newly-proposed derivative with fractional order called beta-derivative. Since none of the commonly used integral transform could be used to derive the solution of the proposed model, I proposed a new integral transform called Atangana-Transform, and used it, together with some iterative technique, to derive the solution of the model.

“My numerical simulations show that the disease is as deadly amongst pregnant women as Ebola,” Abdon said.

Abdon’s research was submitted to one of Springer’s top-tier journals with an impact factor 1.78. The paper was accepted and published February 2015.

Read more about Abdon’s research.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept